Coric, Vladimir, Salloway, Stephen, van Dyck, Christopher H., Dubois, Bruno, Andreasen, Niels, Brody, Mark, Curtis, Craig, Soininen, Hilkka, Thein, Stephen, Shiovitz, Thomas, Pilcher, Gary, Ferris, Steven, Colby, Susan, Kerselaers, Wendy, Dockens, Randy, Soares, Holly, Kaplita, Stephen, Luo, Feng, Pachai, Chahin, Bracoud, Luc, Mintun, Mark, Grill, Joshua D., Marek, Ken, Seibyl, John, Cedarbaum, Jesse M., Albright, Charles, Feldman, Howard H., Berman, Robert M.

Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]

Kieburtz, Karl, McDermott, Michael P., Voss, Tiffini S., Corey-Bloom, Jody, Deuel, Lisa M., Dorsey, E. Ray, Factor, Stewart, Geschwind, Michael D., Hodgeman, Karen, Kayson, Elise, Noonberg, Sarah, Pourfar, Michael, Rabinowitz, Karen, Ravina, Bernard, Sanchez-Ramos, Juan, Seely, Lynn, Walker, Francis, Feigin, Andrew

Objectives: To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.; Design: Double-blind, randomized, placebo-controlled trial.; Setting: Multicenter outpatient trial.; Participants: Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.; […]